Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus chemotherapy in metastatic triple-negative breast cancer
NCT05134194Phase 3Terminated
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jan 2022
- Primary completion
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in triple-negative breast cancer (TNBC), sponsored by Suzhou Suncadia Biopharmaceutical. Started Jan 2022; status: terminated.
02
Drugs
camrelizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05134194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05134194.